HemCon Medical Technologies, Inc. ("HemCon"), an innovative developer of advanced medical products, is proud to announce the signing of an exclusive licensing agreement with Zeria Pharmaceuticals Co. Ltd. ("Zeria"), a leading pharmaceutical and consumer healthcare products company. Through this partnership, Zeria will market, distribute, and sell HemCon's line of revolutionary wound and oral care dressings throughout Japan.
“This partnership will also give HemCon the opportunity to break into the Asian market, which has not been the company's focus until now, and represents a significant opportunity to help provide unique solutions for patient safety and wound care in Japan.”
HemCon's product offerings include a full line of hemostatic dressings with antibacterial properties. The technology, originally developed for use on the battlefield to control severe hemorrhaging, is now used in acute care settings worldwide for bleeding control, wound management, and infection prevention. The HemCon line also includes an over-the-counter line of hemostatic products, as well as a revolutionary oral wound care dressing for oral surgery and periodontal procedures.
Zeria, established in 1955 and listed on the Tokyo Stock Exchange, has a wide-ranging portfolio that includes hemostatic surgical compounds, which the HemCon products will augment. Zeria holds a strong position in the gastroenterology (GI) field and markets products in dermatology and cardiovascular disease. The company also markets a range of consumer healthcare products and medications.